Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (JPRN-jRCT2031250408) titled 'Phase 2b Study to Evaluate Tulisokibart for Rheumatoid Arthritis' on Oct. 2.
Study Type: Interventional
Study Design:
randomized controlled trial, double blind, placebo control, parallel assignment, treatment purpose
Primary Sponsor: Iwamoto Taro
Condition:
Rheumatoid Arthritis
Intervention:
- High-dose tulisokibart group: Subcutaneous administration of high-dose tulisokibart in addition to methotrexate background therapy.
- Medium-dose tulisokibart group: Subcutaneous administration of medium-dose tulisokibart in addition to methotrexate background therapy.
- Low-dose tulisokibart group: Subcutaneous a...